Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 38

The DOI matches its Crossref record.

Assessment of drug-drug interactions caused by metabolism-dependent cytochrome P450 inhibition

Lee, Ji-Yoon, Lee, Sang Yoon, Oh, Soo Jin, Lee, Ki Ho, Jung, Young Suk, Kim, Sang Kyum·2012·Chemico-Biological Interactions
DOI 10.1016/j.cbi.2012.05.007
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cbi.2012.05.007

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 26

  1. VandenBrink, 2010, The role of metabolites in predicting drug–drug interactions: focus on irreversible cytochrome P450 inhibition, Curr. Opin. Drug Discov. Dev., 13, 66
  2. Parkinson, 2011, An evaluation of the dilution method for identifying metabolism-dependent inhibitors of cytochrome P450 enzymes, Drug Metab. Dispos., 39, 1370, 10.1124/dmd.111.038596 · DOI · Paper page
  3. Lee, 2011, Assessment of reactive metabolites in drug-induced liver injury, Arch. Pharm. Res., 34, 1879, 10.1007/s12272-011-1108-x · DOI
  4. Obach, 2007, Mechanism based inactivation of human cytochrome P450 enzymes and the prediction of drug–drug interactions, Drug Metab. Dispos., 35, 246, 10.1124/dmd.106.012633 · DOI
  5. Venkatakrishnan, 2007, Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug–drug interaction risk assessment, Xenobiotica, 37, 1225, 10.1080/00498250701670945 · DOI
  6. Huang, 2008, New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process, J. Clin. Pharmacol., 48, 662, 10.1177/0091270007312153 · DOI · Paper page
  7. Grimm, 2009, The conduct of in vitro studies to address time dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America, Drug Metab. Dispos., 37, 1355, 10.1124/dmd.109.026716 · DOI · Paper page
  8. Lin, 1998, Inhibition and induction of cytochrome P450 and the clinical implications, Clin. Pharmacokinet., 35, 361, 10.2165/00003088-199835050-00003 · DOI · Paper page
  9. Polasek, 2007, In vitro approaches to investigate mechanism-based inactivation of CYP enzymes, Expert Opin. Drug Metab. Toxicol., 3, 321, 10.1517/17425255.3.3.321 · DOI
  10. Fowler, 2008, In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug–drug interactions, AAPS J., 10, 410, 10.1208/s12248-008-9042-7 · DOI
  11. Krippendorff, 2009, Mechanism-based inhibition: deriving KI and kinact directly from time-dependent IC50 values, J. Biomol. Screen., 14, 913, 10.1177/1087057109336751 · DOI
  12. Perloff, 2009, Validation of cytochrome P450 time-dependent inhibition assays: a two-time point IC50 shift approach facilitates kinact assay design, Xenobiotica, 39, 99, 10.1080/00498250802638155 · DOI
  13. Atkinson, 2005, Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography–tandem mass spectrometry analysis, Drug Metab. Dispos., 33, 1637, 10.1124/dmd.105.005579 · DOI
  14. Lim, 2005, Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes, Drug Metab. Dispos., 33, 1211, 10.1124/dmd.104.003475 · DOI
  15. K.S. Lee, S.K. Kim, Direct and metabolism-dependent cytochrome P450 inhibition assays for evaluating drug–drug interactions, J. Appl. Toxicol., in press.
  16. Stresser, 2009, Differential time- and NADPH-dependent inhibition of CYP2C19 by enantiomers of fluoxetine, Drug Metab. Dispos., 37, 695, 10.1124/dmd.108.025726 · DOI
  17. Ring, 2001, Identification of the human cytochromes P450 responsible for the in vitro formation of R- and S-norfluoxetine, J. Pharmacol. Exp. Ther., 297, 1044, 10.1016/S0022-3565(24)29631-2 · DOI
  18. Foti, 2008, CYP2C19 inhibition: the impact of substrate probe selection on in vitro inhibition profiles, Drug Metab. Dispos., 36, 523, 10.1124/dmd.107.019265 · DOI
  19. Berry, 2008, An examination of IC50 and IC50-shift experiments in assessing time-dependent inhibition of CYP3A4, CYP2D6 and CYP2C9 in human liver microsomes, Drug Metab. Lett., 2, 51, 10.2174/187231208783478407 · DOI
  20. He, 1999, Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (ru486), J. Pharmacol. Exp. Ther., 288, 791, 10.1016/S0022-3565(24)38021-8 · DOI
  21. Mayhew, 2000, An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by 22 metabolic intermediate complex formation, Drug Metab. Dispos., 28, 1031, 10.1016/S0090-9556(24)15182-3 · DOI
  22. Naritomi, 2004, Utility of microtiter plate assays for human cytochrome P450 inhibition studies in drug discovery: application of simple method for detecting quasi-irreversible and irreversible inhibitors, Drug Metab. Pharmacokinet., 19, 55, 10.2133/dmpk.19.55 · DOI
  23. Zhou, 2005, Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs, Clin. Pharmacokinet., 44, 279, 10.2165/00003088-200544030-00005 · DOI · Paper page
  24. Watanabe, 2007, Risk assessment for drug–drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process, Drug Metab. Dispos., 35, 1232, 10.1124/dmd.107.015016 · DOI
  25. Parkinson, 2010, System-dependent outcomes during the evaluation of drug candidates as inhibitors of cytochrome P450 (CYP) and uridine diphosphate glucuronosyltransferase (UGT) enzymes: human hepatocytes versus liver microsomes versus recombinant enzymes, Drug Metab. Pharmacokinet., 25, 16, 10.2133/dmpk.25.16 · DOI
  26. Coles, 1984, Effects of modifying structure on electrophilic reactions with biological nucleophiles, Drug Metab. Rev., 15, 1307, 10.3109/03602538409029962 · DOI

Cited by

Metadata

Authors
Lee, J.-Y., Lee, S. Y., Oh, S. J., Lee, K. H., Jung, Y. S., & Kim, S. K.
Venue
Chemico-Biological Interactions
Publisher
Elsevier BV
Published
2012-06
Volume
198
Issue
1-3
Pages
49-56
ISSN
0009-2797
DOI
10.1016/j.cbi.2012.05.007
Cited by
38
References
0
Language
en
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.